BIST10014.200,71▼ 0.00%Bitmine (BMNR) Jumps 11.5% as Investors Double Down on Ethereum BetUSD/TRY47.2752▲ 0.20%Hyundai to Acquire Full Ownership of Boston Dynamics: Robotics Revolution Next PhaseEUR/TRY54.0562▲ 0.30%Dow Jones Futures Rise Amid AI Woes: Taiwan Semi, GE and UnitedHealth Drive Market MovementsBTC/USD$64,158▼ -0.81%Saat ve Saat's IPO Strategy: Stepping Toward Global Brand StatusGOLD6.112,68▲ 0.15%U.S. Time Reform: Permanent Daylight Saving Time Blocked in SenateBRENT$84.86▼ 0.00%U.S. Retirement Savings Crisis: Lessons from Warren Buffett's Warnings July IPO Performance: Investors Reap Gains and Losses with BETAE Leading at 133%BIST10014.200,71▼ 0.00%Bitmine (BMNR) Jumps 11.5% as Investors Double Down on Ethereum BetUSD/TRY47.2752▲ 0.20%Hyundai to Acquire Full Ownership of Boston Dynamics: Robotics Revolution Next PhaseEUR/TRY54.0562▲ 0.30%Dow Jones Futures Rise Amid AI Woes: Taiwan Semi, GE and UnitedHealth Drive Market MovementsBTC/USD$64,158▼ -0.81%Saat ve Saat's IPO Strategy: Stepping Toward Global Brand StatusGOLD6.112,68▲ 0.15%U.S. Time Reform: Permanent Daylight Saving Time Blocked in SenateBRENT$84.86▼ 0.00%U.S. Retirement Savings Crisis: Lessons from Warren Buffett's Warnings July IPO Performance: Investors Reap Gains and Losses with BETAE Leading at 133%

Global MarketsJuly 16, 2026 at 01:50 PM

Erasca (ERAS) Surges 8.9% on Promising Cancer Trial Results

724FinanceGökberk Uçar

Erasca (ERAS) Surges 8.9% on Promising Cancer Trial Results

Erasca (ERAS) stock surged 8.94% to close at $19.50, driven by promising clinical trial results for its cancer treatment candidate. ERAS-0015 showed a 57% tumor reduction in seven pancreatic cancer patients after eight weeks.

■Jefferies raised its price target by 14% to $24, highlighting undervaluation.

■Hedge funds increased to 51 from 32 in Q1, signaling institutional confidence.

■The company plans a lung cancer trial for ERAS-0015 in H1 2027.

The results position Erasca as a key player in cancer therapy. Additional data on ERAS-0015's combination with panitumumab is expected in H1 2027. Investors are valuing the drug's efficacy and safety profile against competitors like daraxonrasib.